Tetsuro Matano, AIDS Research Center, April 2, 2013

The New York-based International AIDS Vaccine Initiative (IAVI) and the Japan-based biotech DNAVEC Corporation announced the start of a Phase I clinical trial of an HIV vaccine candidate using Sendai virus (SeV) vector at three locations including England and Rwanda. The SeV vector AIDS vaccine system has been developed by AIDS Research Center, National Institute of Infectious Diseases and Institute of Medical Science, University of Tokyo.

Press release from IAVI on April 1, 2013

http://www.iavi.org/Information-Center/Press-Releases/Pages/IAVI-AND-PARTNERS-INITIATE-PHASE-I-TRIAL-OF-A-NOVEL-AIDS-VACCINE-REGIMEN.aspx

Information on this project in IAVI Web

http://www.iavi.org/Information-Center/Publications/Pages/AIDS-Vaccine-Development-in-Japan.aspx